{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-025293","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2023-07-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.226457+00:00","generated_at":"2026-06-13T04:55:16.534755+00:00","sec_items":["1.01","2.04","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"Avalo enters forbearance on venture debt default and signs non-binding LOI to sell 800 series for $150K upfront","bullets":["Forbearance until Aug 15, 2023; company must keep cash >= $3M plus 100% of future equity proceeds.","Preliminary cash and equivalents ~$4.5M as of July 20, 2023 (unaudited).","Non-binding LOI to sell AVTX-801, -802, -803 for $150K upfront, up to $45M in FDA approval milestones.","Holders asserted default due to material adverse change; forbearance halts enforcement until mid-August."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-025293","json":"https://secwatch.observer/filing/0001628280-23-025293.json","markdown":"https://secwatch.observer/filing/0001628280-23-025293.md","text":"https://secwatch.observer/filing/0001628280-23-025293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023025293/0001628280-23-025293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023025293/avtx-20230720.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T04:55:16.534755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"883be7f5f3e287b4f1ec26bc53de0762ab338349","claim":"Avalo Therapeutics, Inc. entered into Forbearance Agreement with the Holders (effective 2023-07-20).","evidence_excerpt":"As of July 20, 2023, the Holders asserted that a default and event of default has occurred due to a material adverse change in the Company’s business (the “Existing Default”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023025293/0001628280-23-025293-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"the Holders"},{"label":"Effective","value":"2023-07-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}